Abstracts tagged "polyarthritis"

Abstract Number: 070 • 2020 Pediatric Rheumatology Symposium
The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis
Rebecca Trachtman¹, Daniel J. Lovell ², Rula Issa ¹, Stephanie Pan ¹, Karen Wilson ¹ and Karen Onel ³, ¹Icahn School of Medicine at Mount Sinai, New York, ²Cincinnati, ³Hospital for Special Surgery, New York
Background/Purpose: Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA wherein more than four joints are affected with arthritis; it is characterized by unpredictable…
Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Saumya Joshi¹, Yujuan Zhang ¹ and Trevor Davis ², ¹Tufts Medical Center, Boston, Massachusetts, ²Norwell, Massachusetts
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…
Abstract Number: L22 • 2019 ACR/ARP Annual Meeting
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Hermine Brunner¹, Olga Synoverska ², Tracy Ting ³, Carlos Abud Mendoza ², Alberto Spindler ², Yulia Vyzhga ², Katherine Marzan ³, Vladimir Keltsev ², Irit Tirosh ², Lisa Imundo ³, Rita Jerath ³, Daniel Kingsbury ³, Betul Sozeri ², Sheetal Vora ³, Sampath Prahalad ³, Elena Zholobova ², Yonatan Butbul Aviel ², Vyacheslav Chasnyk ², Melissa Lerman ³, Kabita Nanda ³, Heinrike Schmeling ³, Heather Tory ³, Yosef Uziel ², Diego Oscar Viola ², Holly Posner ⁴, Keith Kanik ⁵, Ann Wouters ⁴, Cheng Chang ⁵, Richard Zhang ⁴, Irina Lazariciu ⁶, Ming-Ann Hsu ⁵, Ricardo Suehiro ⁷, Alberto Martini ², Daniel J. Lovell ³ and Nicolino Ruperto ⁸, ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ⁴Pfizer Inc, New York, New York, ⁵Pfizer Inc, Groton, Connecticut, ⁶IQVIA, Montreal, Quebec, Canada, ⁷Pfizer Inc, Collegeville, Pennsylvania, ⁸PRINTO, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
Abstract Number: 2705 • 2019 ACR/ARP Annual Meeting
Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis
Anne McHugh¹, Avis Chan ², Carolyn Herrera ², Margo Thienemann ² and Jennifer Frankovich ², ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto
Background/Purpose: Mental health disorders are thought to be common in patients with rheumatic disease, but studies examining behavioral issues in patients with juvenile idiopathic arthritis…
Abstract Number: 1448 • 2018 ACR/ARHP Annual Meeting
Clinical Impact of Articular Ultrasound in Diagnosis and Follow-up of Patients with Polyarthritis
Justine Lafleur-Careau¹, François Taschereau¹, Artur J de Brum-Fernandes², Alessandra Bruns³, Gilles Boire⁴ and Ariel Masetto⁵, ¹Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Rhumatologie, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Centre Hospitalier Universitaire de Sherbrooke (CHUS), Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, AB, Canada
Background/Purpose: It is well established in the literature that musculoskeletal ultrasound (MSUS) is more sensitive than clinical examination in the detection of synovitis. MSUS can…
Abstract Number: 151 • 2015 ACR/ARHP Annual Meeting
Residual Synovitis in Ultrasound (US) Is Associated with an Evolution Towards Rheumatoid Arthritis (RA) in Patients with Inflammatory Polyarthralgia without ANTI-Citrulinated Antibodies (ACPA)
Pascal Zufferey^1,2,3, Claudia Rebell Jr.⁴, Alexandre Dumusc⁵, Mauro lucini⁴, Juerg Hains⁶, Alexander K. So Sr.⁷ and Charles Benaim⁸, ¹Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ²Pierer Decler, Chuv, Lausanne, Switzerland, ³Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ⁴DAL, RHU/CHUV, lausanne, Switzerland, ⁵RHU/CHUV, lausanne, Switzerland, ⁶DAL, RHU/CHUV, Lausanne, Syria, ⁷Service De Rhumatologie, CHUV, Lausanne, Switzerland, ⁸DAL, MPR, Lausanne, Switzerland
Background/Purpose: In ACPA positive patients, subclinical synovitis as observed by US has been demonstrated in pre RA patients and seems to be predictive for future…
Abstract Number: 165 • 2015 ACR/ARHP Annual Meeting
Validation of a New Ultrasound Criteria for Subclinical Synovitis in Chronic Inflammatory Polyarthritis
Julio Ramírez¹, Jose Inciarte-Mundo², Andrea Cuervo¹, Virginia Ruiz-Esquide², M. Victoria Hernández³, Raimon Sanmarti² and Juan D. Cañete², ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ³Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: We have previously reported that patients with subclinical synovitis defined by synovial hypertrophy grade >2 (SH>2) plus power Doppler (PD) signal had higher disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].